XNK Therapeutics’ Evencaleucel gains EMA recommendation

2024-01-16

临床2期基因疗法细胞疗法免疫疗法

XNK Therapeutics’ Evencaleucel gains EMA recommendation

Preview

来源: Pharmaceutical Technology

Supporting XNK Therapeutics’ work is a team that includes experts in NK cell research. Credit: Gorodenkoff/Shutterstock.com.

Preview

来源: Pharmaceutical Technology

XNK Therapeutics, a Sweden-based immunotherapy company, has received scientific recommendation from the European Medicines Agency’s (EMA) Committee for Advanced Therapies for its product Evencaleucel.

Evencaleucel is classified as a Somatic Cell Therapy Medicinal Product.

The classification places Evencaleucel within the category of Advanced Therapy Medicinal Products. The platform utilised by XNK to manufacture the product is designed to produce autologous natural killer (NK) cell-based drug candidates.

The candidates are developed to act on malignant ailments, both as mono and combination therapies.

The platform features a closed manufacturing system, which is pivotal for developing NK cell-based products.

The manufacturing process involves the careful expansion and activation of NK cells derived from the peripheral blood of cancer patients.

XNK has a pipeline that includes treatments for both haematological malignancies and solid tumours.

Evencaleucel is the company’s most advanced product and is currently undergoing Phase II clinical trials, evaluating the therapy along with isatuximab, a CD38 antibody, to treat multiple myeloma.

Another asset, XNK02, is in advanced preclinical studies in partnership with the MD Anderson Cancer Center Cancer Center to potentially treat acute myeloid leukaemia.

XNK03, aimed at treating bladder cancer, is in preclinical studies in partnership with the Karolinska University Hospital.

Supporting XNK Therapeutics’ innovative work is a team that includes experts in NK cell research.

The company also benefits from an approved in-house good manufacturing practice facility.

XNK Therapeutics chief medical officer Peter Hovstadius stated: “We are very pleased with EMA’s scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline

The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构